Instrument Inactif

Autres langues Impax Laboratories Inc Nasdaq

Actions

US45256B1017

Produits pharmaceutiques

Autres langues

23/09	Amneal Pharmaceuticals' Biosimilars, Specialty Growth Reshape Earnings Profile, Oppenheimer Says
21/09	Amneal Pharmaceuticals Shares Rise After FDA Approval for Lanreotide Injection
21/09	Top Midday Gainers
21/09	Ipsen Shares Fall After Early Launch of U.S. Generic Rival
18/09	Stocks to Watch : Paramount Skydance, Warner Bros. Discovery, Accenture, Amneal Pharmaceuticals
18/09	Amneal Gets FDA Approval for Generic Hormone Drug
18/09	Amneal Pharmaceuticals Secures FDA Approval for Lanreotide Injection
18/09	Amneal Announces FDA Approval and Launch of Lanreotide Injection
18/09	Amneal Pharmaceuticals, Inc. Announces FDA Approval And Launch Of Lanreotide Injection
03/09	US FDA is working with manufacturers to boost estrogen patch supply amid access concerns
26/08	U.S. research roundup- Intuit, MongoDB, Zscaler
17/08	Amneal Completes Acquisition Of Kashiv
13/08	Amneal Pharmaceuticals Insider Sold Shares Worth $3,771,050, According to a Recent SEC Filing
13/08	Amneal Pharmaceuticals Insider Sold Shares Worth $2,563,517, According to a Recent SEC Filing
10/08	Amneal Pharmaceuticals Completes Kashiv BioSciences Acquisition
10/08	Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
10/08	Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
10/08	Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv BioSciences, LLC from Tarsadia Investments LLC and others.
03/08	Amneal Pharmaceuticals Has Favorable Setup for Growth With Product Approvals, Launches, UBS Says
30/07	Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year of 2026
30/07	Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	Amneal Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Raises 2026 Guidance
30/07	(AMRX) Amneal Pharmaceuticals Expects Full Year 2026 Revenue Range $3.10B - $3.20B, vs. FactSet Est of $3.11B
30/07	(AMRX) Amneal Pharmaceuticals Expects Full Year 2026 Adjusted EPS Range $0.96 - $1.06, vs. FactSet Est of $0.97
30/07	Earnings Flash (AMRX) Amneal Pharmaceuticals, Inc. Reports Q2 Revenue $796.2M, vs. FactSet Est of $768.2M